Secukinumab scFv-Transferrin Fusion for Barrier-Penetrating Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Many antibodies face challenges in crossing biological barriers such as the blood-brain barrier and blood-eye barrier, and entering cancerous cells due to their size and lack of transcytosis, limiting their efficacy and application in certain diseases.
Innovation Solution
A single-chain variable fragment (scFv) antibody is designed to conjugate with the N-methyl lobe of transferrin protein, utilizing transferrin receptor-mediated endocytosis for enhanced cellular uptake and incorporating cleavable linkers that respond to specific cellular environments for targeted delivery and release.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a whole antibody is used, then effector functions and half-life are enhanced, but penetration across biological barriers is reduced
Solution Approach 1:
The antibody is segmented into functional components: the scFv fragment retains antigen-binding capability while the Fc region is modified or removed. This segmentation allows the antibody to cross biological barriers more effectively while maintaining necessary effector functions through alternative mechanisms such as transcytosis promotion.
Solution Approach 2:
The patent introduces an intermediary mechanism (transcytosis promotion) that facilitates the transport of the scFv fragment across biological barriers. This intermediary approach allows the smaller scFv to penetrate barriers that would normally block whole antibodies, while the Fc region can still mediate effector functions when needed.
2Length of moving object
If an scFv is used, then penetration across biological barriers is improved, but effector functions are reduced
Solution Approach 1:
The Fc region is extracted or modified from the full antibody to create an scFv fragment. This extraction enables improved penetration across biological barriers due to the smaller size, while effector functions are maintained through alternative means such as Fc region modification or use of transcytosis promotion mechanisms.
Solution Approach 2:
The patent applies parameter changes to the Fc region, such as modification of its structure or properties, to enable it to fulfill effector functions despite the reduced size of the scFv fragment. This parameter modification allows the scFv to maintain therapeutic efficacy while achieving better barrier penetration.
3Reliability
If a whole antibody is used, then effector functions are enhanced, but delivery to inflamed tissues is reduced
Solution Approach 1:
The antibody is divided into scFv fragments that can more effectively reach inflamed tissues due to their smaller size and improved permeability. The segmentation allows these fragments to penetrate inflamed tissues better while maintaining the ability to bind target antigens and exert effector functions through modified Fc regions.
4Productivity
If an scFv-transferrin conjugate is created, then cellular uptake is enhanced, but device complexity is increased
Solution Approach 1:
The scFv fragment is merged with the transferrin protein to create a conjugate that utilizes the transferrin receptor-mediated endocytosis pathway for enhanced cellular uptake. This merging combines the barrier-penetrating capability of the scFv with the cellular uptake mechanisms of the transferrin-conjugate system.
Solution Approach 2:
The transferrin protein serves multiple functions: it acts as a carrier for the scFv fragment, facilitates receptor-mediated endocytosis, and can be cleaved to release the scFv inside the cell. This multi-functionality reduces the need for additional complex components in the conjugate structure.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The scFv-transferrin conjugate achieves improved penetration across biological barriers, enhances therapeutic efficacy by prolonging interaction with targets, and reduces off-target effects through controlled release within target cells.
Implementation Method 1
utilizing transferrin receptor-mediated endocytosis for enhanced cellular uptake
Implementation Method 2
incorporating cleavable linkers that respond to specific cellular environments for targeted delivery and release
Data Source
AI summary
The efficacy and indication of secukinumab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.